Cargando…
Beta-blockers and physical frailty in patients with end-stage liver disease
AIM: To investigate beta-blocker (BB) use in patients with cirrhosis and determine their effects on physical frailty and overall survival. METHODS: Adult outpatients with cirrhosis listed for liver transplantation underwent testing of physical frailty using the performance-based Liver Frailty Index,...
Autores principales: | Kuo, Selena Z, Lizaola, Blanca, Hayssen, Hilary, Lai, Jennifer C |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6127661/ https://www.ncbi.nlm.nih.gov/pubmed/30197482 http://dx.doi.org/10.3748/wjg.v24.i33.3770 |
Ejemplares similares
-
Nonselective beta-blocker use is associated with increased hepatic encephalopathy-related readmissions in cirrhosis
por: Fallahzadeh, Mohammad Amin, et al.
Publicado: (2022) -
Usefulness of vonoprazan, a potassium ion-competitive acid blocker, for primary eradication of Helicobacter pylori
por: Yamada, Shinya, et al.
Publicado: (2016) -
End-stage renal disease is associated with increased post endoscopic retrograde cholangiopancreatography adverse events in hospitalized patients
por: Sawas, Tarek, et al.
Publicado: (2018) -
Angiotensin converting enzymes inhibitors or angiotensin receptor blockers should be continued in COVID-19 patients with hypertension
por: Tian, Ci, et al.
Publicado: (2021) -
Increased end-stage renal disease risk in patients with inflammatory bowel disease: A nationwide population-based study
por: Park, Seona, et al.
Publicado: (2018)